inhibiting input to the spinal dorsal horn neurons. 11 Several phase 3 studies show that duloxetine is an effective treatment for painful diabetic neuropathy. [12] [13] [14] [15] Based on these trials, our hypothesis was that duloxetine would ameliorate chemotherapy-induced peripheral neuropathic pain as well. A randomized phase 3 trial was conducted to test this hypothesis.
METHODS

STUDY DESIGN
The Cancer and Leukemia Group B (CALGB/Alliance) conducted a randomized phase 3 double-blind, placebocontrolled crossover trial to assess whether 60 mg of duloxetine taken orally once daily decreases the severity of chemotherapy-induced peripheral neuropathy (CALGB-170601, NCT00489411). The primary hypothesis was that duloxetine would be more effective than placebo in decreasing the average pain score after a 5-week treatment period. Secondary aims were to assess duloxetine's effect on QOL and function and on adverse events. The study was approved by each site's institutional review board, and participants provided signed informed consent. Enrollment occurred between April 2008 and March 2011. Study follow-up was completed July 2012.
Patients
Using the National Cancer Institute's (NCI's) Clinical Trials Support Unit mechanism to facilitate accrual, participants were recruited from 8 multisite NCI-funded cooperative research networks, resulting in a geographically diverse population of patients distributed throughout the United States. The diagnosis of chemotherapyinduced peripheral neuropathy was determined based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove numbness or paresthesias beginning after neurotoxic chemotherapy. Eligible patients were 25 years or older, had at least grade 1 sensory pain based on the NCI Common Terminology Criteria for Adverse Events version 3.0 grading scale, and reported 4 on a 10-point scale, average neuropathic pain, for 3 or more months after completing chemotherapy. Patients with any cancer diagnosis or stage were potentially eligible. To diminish the likelihood that symptoms would spontaneously resolve over the course of the study, efficacy data were obtained over 5 weeks.
Initially, patients who had received paclitaxel or oxaliplatin could participate, but eligibility was later expanded to allow prior treatment with single-agent docetaxel, nanoparticle albumin-bound paclitaxel, or cisplatin. Prior or ongoing treatment with other neurotoxic chemotherapeutic agents was not allowed. Participants with a documented medical history of neuropathy from any type of nerve compression (eg, carpal or tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy), leptomeningeal carcinomatosis, severe depression, suicidal ideation, bipolar disease, alcohol abuse, a major eating disorder, and markedly abnormal renal or liver function tests were ineligible.
Despite scant evidence supporting the association between certain comorbid illnesses and the risk of developing severe pain, 9, 16 patients with diabetes mellitus and peripheral vascular disease, whose pain was thought to be from chemotherapy-induced peripheral neuropathy, were eligible but were defined as high risk. We controlled for comorbid illness as a potential confounder by assigning equal numbers of high-risk patients to each treatment group. Concurrent use of other drugs known to influence serotonin levels was not allowed. Concomitant use of selected analgesics was allowed (eg, opioids, acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs), but only patients receiving stable doses in the 2 weeks before randomization could participate: (1) no new analgesics were added, (2) no analgesics were discontinued, and (3) the weekly 24-hour total analgesic dose did not fluctuate up or down by more than 10% in the 2 weeks before study registration.
Intervention
Eligible patients were randomized using a 1:1 allocation ratio to either group A or group B. In this crossover design, group A received 60 mg of duloxetine daily during the initial treatment period and placebo at crossover period. Group B received placebo as initial treatment and duloxetine as the crossover treatment. Randomization, provided by the CALGB/Alliance Statistical Center, was stratified by neurotoxic drug class (taxanes vs platinums) and by pain risk (high risk vs no risk). A computer-generated kit number was used to order the blinded study drug from a distribution center. Drug labels were applied to the capsule bottles at the distribution center before being mailed to study sites; thus, all patients and personnel were blinded to the treatment assignment.
The initial (weeks 1-5) and crossover (weeks 8-12) treatment periods each consisted of receiving 1 capsule of either placebo or 30 mg of duloxetine for the first week and 2 capsules of either placebo or 30 mg of duloxetine for 4 weeks. The initial 5-week period was followed by a 2-week washout period for a total study duration of 14 weeks (FIGURE 1).
Data Collection and Instruments
Patient-reported pain severity and functional interference was assessed weekly using the well-validated Brief Pain Inventory Short Form (BPI-SF). [17] [18] [19] The BPI-SF contains 4 items assessing average, worst, least, and immediate pain severity in the last 24 hours. Pain severity items are scored using an 11point numeric rating scale (0, no pain; 10, pain as bad as you can imagine). The BPI-SF worse pain severity item has been shown to be reliable and valid for use as a single item. 20 However, we chose average pain severity as our primary outcome measure based on recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT). 21 In addition, average pain has been defined as the primary out-come measure in numerous duloxetine phase 3 studies involving patients with peripheral and central neuropathic pain conditions due to diabetic-and oxaliplatin-induced neuropathy, fibromyalgia, and osteoarthritis [13] [14] [15] [22] [23] [24] [25] [26] [27] [28] [29] [30] and thereby was chosen to facilitate comparison of our findings across similar studies. The minimal clinically important difference in pain severity was defined for the current study as a 0.98 difference in mean average pain severity between the duloxetine and placebo groups. Using an accepted method for assessing the influence of pain on function, [13] [14] [15] [26] [27] [28] [29] 7 BPI-SF items were used to quantify the degree to which pain interfered with daily activities or function (0, does not interfere; 10, completely interferes). The 7 items were summed to obtain a total interference score. Patient-reported QOL was assessed using the Functional Assessment of Cancer Treatment, Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale on day 1 of weeks 1, 6, 8, and 13. The assessment's strong psychometric properties have been previously demonstrated. [31] [32] [33] The instrument contains 11 questions assessing numbness, tingling, and discomfort in the hands or feet; difficulty hearing; tinnitus; joint pain or muscle cramps; weakness; or trouble walking, buttoning buttons, or feeling small shapes when placed in the hand. Items are scored from 0 to 4 (0, not at all; 4, very much) and summed (total score range, 0-44). 33 Because there are no published data defining a cut point for determining a clinically important change in the score, we defined a 2-to 3-point change as a clinically meaningful improvement in QOL per published recommendations specific to similar measures. [34] [35] [36] [37] Using the NCI CTCAE version 3.0, adverse events were reported weekly and graded on a 0 to 4 scale (0, normal; 4, life-threatening) 38 as was baseline sensory chemotherapy-induced peripheral neuropathy (0, normal; 1, asymptomatic, weakness on physical examination, loss of reflexes, or paresthesias not interfering with function; 2, weakness and sensory alterations interfering with function; 3, weakness and sensory alterations interfering with activities of daily living or requiring bracing or assistive devices; and 4, life threatening, paralysis, or disabling).
Statistical Analyses
Statistical analyses were performed by CALGB/Alliance statisticians. The primary study end point was the change from start to end of the initial treatment period (week 1 to week 5, measured on day 1 of weeks 1 and 6) in average pain based on the BPI-SF average pain severity item. The comparison of interest was the difference between the 2 treatment groups in pain change. With 232 patients (assuming 20% attrition), the study had 90% power (2sided ␣ of .05) to detect a 0.98-point change between the 2 groups assuming a standard error of 0.31. The target difference of 0.98 is consistent with diabetic research. 30 We calculated the proportion of patients experiencing any decrease in pain. Also, using another accepted approach for assessing clinical significance, [13] [14] [15] [22] [23] [24] 26 ,39-41 we conducted an exploratory responder analysis based on the proportion of patients in both groups who experienced a 30% (or 50%) decrease in pain severity. Relative risk-benefit was the proportion of patients with 30% (or 50%) pain reduction in the duloxetine group relative to that in the placebo group. It was calculated from contingency tables. We also conducted an exploratory subgroup analyses based on chemotherapy class.
Secondary end points were change in chemotherapy-induced peripheral neuropathy-related QOL, measured by the total score of the FACT/GOG-Ntx, and degree of pain-related functional interference based on the BPI-SF interference score. Changes attributable to ini- tial treatment were defined as the difference between the week 1 and week 5 scores (measured on day 1 of weeks 1 and 6). Changes for crossover treatment used week 8 and week 12 scores (measured on day 1 of weeks 8 and 13).
To test for a group effect during the initial treatment period on the primary and secondary end points, we used 3 separate models of analysis of covariance, each stratified by neurotoxic agent and risk of painful chemotherapyinduced peripheral neuropathy, and including the baseline measure of the corresponding end point. Least square means and their 95% confidence intervals were taken from analysis of covariance models. Additionally, for the primary end point, generalized estimating equations were used to determine whether there was a treatment effect when combining data from both the initial and crossover periods. Multiple imputation and pattern-mixture model were used to evaluate the pattern and potential influence of missing values for the primary end point (eAppendix available at www.http://www.jama .com). To univariately compare treatment groups, the Wilcoxon rank test was used for continuous variables and the 2 test for proportions. The 95% confidence intervals for proportions used exact binomial methods. Analyses included only patients who began protocol therapy. Statistical analyses with 2-sided significance threshold of PϽ.05 were performed using SAS ver-sion 9.2 (SAS Institute Inc). Data quality was ensured by review of data by the CALGB/Alliance Statistical Center and by the study chairperson. The study underwent standard biannual monitoring by the CALGB/Alliance data and safety monitoring board with 1 formal interim efficacy analysis resulting in study continuation.
RESULTS
Patients
Patient disposition for the initial treatment period is illustrated in Figure 1 . Of the 231 patients recruited to the study, 115 were allocated to group A (duloxetine first, placebo second), and 116 to group B (placebo first, duloxetine second). Eleven patients never received treatment, leaving 220 treated patients. The dropout rate due to adverse events in the duloxetine-first group was 11% vs 1% in the placebofirst group (PϽ.001). Despite using an intent-to-treat analysis approach, 6 patients (1 in group A; 5 in group B) during the initial treatment period were excluded from the primary analysis because they provided no data at all. This resulted in a 19% dropout rate.
Patient characteristics are described in the TABLE. Both groups were similar at baseline, except for the mean (SD) pain score of 6.1 (1.7) in group A, duloxetine first, and 5.6 (1.6) in group B, placebo first (P=.02).
Pain (Primary Outcome)
At the end of the initial treatment period, patients in the duloxetine-first group reported a larger decrease in average pain (mean change score, 1.06; 95% CI, 0.72-1.40) than those in the placebo-first group (mean change score, 0.34; 95% CI, 0.01-0.66; P = .003; FIGURE 2). The effect size attributed to duloxetine was moderately large at 0.513. 42 The observed mean difference in the average pain score between the duloxetine-first and placebo-first groups was 0.73 (95% CI, 0.26-1.20). Results of the sensitivity analysis taking missing data into consideration are consistent with the primary findings of the trial (eTables 1 and 2 available at http://www.jama.com): multiple imputation (P = .002) and patternmixture model control-based imputation (P=.004). The primary analysis P value lies between the slightly more liberal multiple imputation approach and the more conservative patternmixture model. A post hoc power calculation is provided in the eAppendix.
Of the patients treated with duloxetine first, 59% reported any decrease in pain vs 38% of patients treated with placebo first. Thirty percent of duloxetine-treated patients reported no change in pain and 10% reported increased pain. Based on the exploratory responder analysis, the proportion of patients achieving various levels of pain reduction is illustrated in FIGURE 3. Compared with placebo, the relative risk of experiencing a 30% pain reduction with duloxetine was 1.96 (95% CI, 1.15-3.35) and experiencing a 50% pain reduction was 2.43 (95% CI, 1.11-5.30; eTable 3).
Although the study was powered to detect differences between treatments as main effects only, in exploratory analyses, we examined the potential interaction between treatment group and chemotherapy class. Results suggested that patients who received platinums (oxaliplatin) experienced more benefit from duloxetine than those who received taxanes (P = .13). The ob- Week
Crossover treatment period
Mean Pain Score
Duloxetine first (group A) Placebo first (group B) Duloxetine second (group B)
Placebo second (group A)
The mean average pain score was measured on the first day of each week in the initial and crossover treatments periods. Day 1 of the first week begins the initial treatment period. Day 1 of week 6 begins the washout period when patients received 1 capsule of duloxetine or placebo. Patients took no drug during week 7. Error bars represent 95% CIs. We also concurrently evaluated changes in pain severity during the crossover treatment period. After adjusting for the study stratifiers (chemotherapy class and pain risk), there was a statistically significant treatment effect on change in pain score (PϽ .001), but an order effect was not significant (P = . 43 ). An additional generalized estimating equation model with carryover effect was performed.
The treatment remained significant (P = .002), whereas the period (P =.55) and carryover (P=.95) effects were not. The change in mean pain score during the crossover treatment period for group A (placebo second) was 0.41 (95% CI, 0.06-0.89) and for group B (duloxetine second) was 1.42 (95% CI, 0.97-1.87). The mean difference between the 2 groups in mean change score during the crossover period was 1.01 (95% CI, 0.36-1.65).
Secondary Outcome
Pain Interference With Daily Function.
At the end of the initial treatment period, when compared with placebo, patients treated with duloxetine first reported a greater decrease in the amount that pain had interfered with daily functioning (P=.01; eFigure 1). The change in mean interference score for patients treated with duloxetine first was 7.9 (95% CI, 5.4-10.5) vs 3.5 (95% CI, 1.1-5.9) for patients treated with placebo first. The mean difference between the 2 groups in mean change score was 4.40 (95% CI, 0.93-7.88).
Quality of Life. Pain-related QOL improved to a greater degree for those treated with duloxetine during the initial treatment than for those treated with placebo. The mean change in the FACT/ GOG-Ntx total score was 2.44 (95% CI, 0.43-4.45) for patients treated with duloxetine first vs 0.87 (95% CI, 1.09-2.82) for patients treated with placebo first (P=.03). The mean difference between the 2 groups in mean change score was 1.58 (95% CI, 0.15-3.00; P=.03).
Adverse Effects. No hematologic or grade 4 (moderately severe) or 5 (severe) adverse events were reported. In the initial treatment period, 16% treated with duloxetine and 27% treated with placebo reported grade 2 (mild) and 7% treated with duloxetine and 3% treated with placebo reported grade 3 (moderate) nonhematologic adverse events. Fatigue (7%), insomnia (5%), and nausea (5%) were the most common adverse effects reported by patients treated by duloxetine, whereas somnolence (8%), insomnia (7%), and fatigue (5%) were the most common adverse effects reported by patients treated with placebo (eTable 7 available at http: //www.jama.com).
Other Findings
Nonpainful Symptoms. After the initial treatment period, 41% of patients treated with duloxetine reported a decrease in numbness and tingling in the feet (95% CI, 31%-52%) vs 23% of patients treated with placebo (95% CI, 15%-33%). The trend held through the crossover period with 41% of patients treated with duloxetine (95% CI, 31%-53%) vs 21% of patients treated with placebo (95% CI, 13%-32%). The proportion of patients with improved hand numbness and tingling at the end of the initial treatment period was similar among those treated with duloxetine (36%) and those treated with placebo (34%).
Ancillary Analgesics. Compared with group A (duloxetine first), a higher proportion of those in group B (placebo first) were taking concomitant medications at the start (43% of patients in group B vs 31% in group A) and at the end of the initial treatment period (36% in group B vs 29% in group A).Twenty-seven percent of patients who started out taking concomitant medications in the group A discontinued all medications by the end of the initial treatment period compared with 19% of patients in group B. The plot shows the proportion of patients achieving various levels of pain reduction at the completion of the initial treatment period.
COMMENT
Treatment of painful chemotherapyinduced peripheral neuropathy continues to be a challenge because most drugs tested to date have fallen short of providing adequate pain relief. [43] [44] [45] [46] [47] To our knowledge, the current study is the first large phase 3 trial to elucidate an effective intervention for painful chemotherapy-induce peripheral neuropathy caused by platinum and taxane agents (mainly paclitaxel or oxaliplatin). During initial treatment, the mean difference between the 2 groups of the change in average pain score was 0.73 (P=.003), which compares favorably to mean differences in average pain scores (range, 0.60-0.98) observed in patients receiving duloxetine for US Food and Drug Administration-approved indications for painful diabetic neuropathy, fibromyalgia, and osteoarthritis (eTable 8 available at www.http://www.jama .com). 13, 26, 30 The observed mean difference in the average pain score between the duloxetine and placebo groups in patients treated with platinum was larger than results reported by Goldstein and colleagues 13 (FIGURE 4) . However, duloxetine-related clinically meaningful improvement in other painful conditions may not be directly comparable with painful chemotherapy-induced peripheral neuropathy. In addition to the magnitude of the improvement, several other factors should be considered when judging clinical significance, such as the treatment effect size. 39 Our results revealed a moderately large treatment effect size (0.513). Based on the IMMPACT recommendations, clinical meaningfulness is also based on the results of a responder analysis, specifically the proportion of patients experiencing a 30% or a 50% improvement in painseverity. 21, 39, 48 A10%to20%decrease in pain severity is considered to represent a minimal clinically important change, a 30% change represents a moderately important improvement and a 50% change represents a substantially important improvement. 21, 39, 48 Duringinitialtreatment, the mean change in average pain score reportedbypatientstreatedwithduloxetine inthecurrentstudywas1.06,animprove-ment of approximately 10% that is consistent with the IMMPACT definition of a minimal clinically important difference. In addition, results of the exploratory responder analysis suggest that the relative risk of experiencing a 30% and 50% improvement in pain severity statistically favored duloxetine.
Other factors to consider when judging clinical significance include how quickly the drug takes effect, tolerability, and the drug's influence on other efficacy end points such as function and QOL. 39 In the current study, pain scores decreased in patients treated with duloxetine relatively quickly, within the first week of therapy ( Figure 2 ). Consistent with our results (eTable 7), several studies show that duloxetine is safe and welltolerated. 13, 14, 26, 30, [49] [50] [51] Furthermore, duloxetine is associated with improved function and QOL. Therefore, after considering the many factors in addition to the magnitude of improvement in pain scores, study results strongly suggest that duloxetine treatment is associated with a clinically meaningful improvement in chemotherapy-induced peripheral neuropathic pain.
Resultsfromourexploratorysubgroup analysis lend support to the premise that differences in pathophysiologic mechanisms may help to explain duloxetine response rate variations across neuropathic painconditions.Justasresponseratesmay vary when duloxetine is used to treat diabetic vs chemotherapy-induced peripheral neuropathy due to differences in nerve injury mechanisms, 16, [52] [53] [54] [55] the mechanisms of taxane-vs platinuminduced peripheral nerve injury are quite different, 16 possibly explaining why patients treated with platinum reported less pain in the current study.
The current trial has several strengths and limitations. The strengths include the prospective, randomized, placebocontrolled trial design and the geographically diverse sample. Regarding limitations, first, there was an imbalance in the dropout rate due to adverse effects in patients treated with duloxetine vs placebo (11% vs 1%, respectively), despite similar adverse effect rates in both groups. One reason for this differential in the dropout rate may be the higher proportion of grade 3 adverse events reported by patients treated with duloxetine. These patients may have been able to guess which drug they were taking, and those experiencing no or minimal pain relief may have dropped out.
Another potential study limitation has to do with how baseline pain was determined. Oncology providers commonly use the NCI CTCAE, or other similar grading scales, to guide a history and physical examination focused on chemotherapy-induced peripheral neuropathy and to grade its severity. 9, 16 Therefore, we relied on standard CTCAE-guided practices for determining severity at baseline. We did not specifically train the examiners regarding CTCAE use because its grading is deeply embedded into oncology practice. Of note, despite its everyday use in oncology clinical settings, the CTCAE is known for its suboptimal interrater reliability and poor sensitivity to detect subtle changes. 32, [56] [57] [58] [59] [60] As such, use of the CTCAE could have resulted in misdiagnosis. Despite its limitations, CTCAE use is consistent with community and academic clinical practice, 9 and thus the generalizability of our findings is enhanced. Other limitations are that changes in concurrent ancillary analgesic dosage were not assessed, study findings may not be applicable to patients with painful chemotherapy-induced peripheral neuropathy caused by other neurotoxic agents, and the study did not address long-term duloxetine treatment (beyond 5 weeks). Despiteduloxetine'sacceptableadverse effect profile, the risk of duloxetine-drug interactions should not be overlooked. Duloxetine should not be used with other drugs that inhibit serotonin reuptake due to the associated increased risk of serotonin syndrome. 61 Also, because duloxetine is a moderate cytochrome (CYP) P450 2D6 enzyme-inhibiter, coadministration with CYP P450 2D6 substrates can lead to increased substrate drug serum concentrations and associated toxicities. [62] [63] [64] [65] Concurrent use of duloxetine with warfarin, nonsteroidal antiinflammatory drugs, or both may also increase bleeding risk. 61, 66 Lastly, if duloxetineandtamoxifenaretakentogether, duloxetine-induced CYP P450 2D6 enzyme inhibition could inhibit tamoxifen conversion to its active metabolite, endoxifen. 61, 63, 67, 68 In conclusion, 5 weeks of duloxetine treatment was associated with a statistically and clinically significant improvement in pain compared with placebo. Exploratory analyses raise the possibility that duloxetine may work better for oxaliplatin-induced rather than taxaneinduced painful chemotherapy-induced peripheral neuropathy.
